Advertisement

Topics

Latest "OrbiMed Advisors LLC" News Stories

22:42 EDT 22nd October 2017 | BioPortfolio

Here are the most relevant search results for "OrbiMed Advisors LLC" found in our extensive news archives from over 250 global news sources.

More Information about OrbiMed Advisors LLC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about OrbiMed Advisors LLC for you to read. Along with our medical data and news we also list OrbiMed Advisors LLC Clinical Trials, which are updated daily. BioPortfolio also has a large database of OrbiMed Advisors LLC Companies for you to search.

Showing "OrbiMed Advisors" News Articles 1–25 of 857

Sunday 22nd October 2017

First Trust Advisors LP Raises Stake in Bristol-Myers Squibb Company

First Trust Advisors LP raised its holdings in shares of Bristol-Myers Squibb Company by 10.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 433,050 shares of the biopharmaceutical company's stock after acquiring an additional 41,892 shares during the quarter.


Saturday 21st October 2017

Teachers Advisors LLC Acquires 1,777 Shares of Pharmerica Corporation

Teachers Advisors LLC increased its holdings in shares of Pharmerica Corporation by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 98,409 shares of the company's stock after purchasing an additional 1,777 shares during the period.

Friday 20th October 2017

Medigene-Aktie: Leerverkäufer Citadel Advisors II hebt Short-Engagement deutlich an - Aktiennews

Martinsried - Leerverkäufer Citadel Advisors II LLC hebt Netto-Leerverkaufsposition in Medigene-Aktien deutlich an: Die Leerverkäufer des Hedgefonds Citadel Advisors II LLC haben ihr Short-Engageme...


Medigene-Aktie: Leerverkäufer Citadel Advisors II bleibt im Rückwärtsgang - Aktiennews

Martinsried - Leerverkäufer Citadel Advisors II LLC baut Netto-Leerverkaufsposition in Medigene-Aktien wieder ab: Die Leerverkäufer des Hedgefonds Citadel Advisors II LLC bleiben im Rückwärtsgang h...

Thursday 19th October 2017

Sheridan Capital Partners Completes Majority Recapitalization of Smile Doctors in Partnership with Linden Capital Partners and Management

Sheridan Capital Partners (“Sheridan” or “SCP”) announced today it has completed a majority recapitalization of existing portfolio company Smile Doctors (“the Company”). Through the recapitalization, Linden Capital is joining as lead investor while Sheridan and management are both rolling over equity. “Working with the entire Smile D...

Rosalynn Carter Institute for Caregiving Celebrates 30 Years of Supporting Caregivers through Advocacy, Education, Research, and Service

The Rosalynn Carter Institute for Caregiving (RCI) will host a 30th Anniversary Summit to honor its long-standing commitment to family, volunteer, and professional caregivers on Friday, Oct. 27 at Georgia Southwestern University. Americus, GA (PRWEB) October 19, 2017 WHAT: The Rosalynn Carter Institute for Caregiving (RCI) will host a 30th Anniversary Summit to honor its long-standing commitment ...

Wednesday 18th October 2017

Gemini Therapeutics raises $42.5mm in Series A financing

Gemini Therapeutics Inc. (precision medicine for rare genetic diseases and ophthalmology) raised $42.5mm in its Series A fina...

Gemini Therapeutics raises $2mm in seed round

Gemini Therapeutics Inc. (gene therapy for rare and ophthalmic diseases) raised $2mm in its seed financing round with OrbiMed...

Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy

Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A for the therapeutics business, which is focused on genetic causes for the condition.

Blade Therapeutics Announces Selection of a Clinical Development Candidate and Funding of the Second Tranche for its Series B Financing

Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, today announced that it has nominated a clinical development candidate for its lead program focused on small molecule inhibitors that selectively target certain intracellular cysteine proteases. Selection of the clinical...

Today's Viridian #Cannabis Deal Tracker for Week Ended October 13, 2017

October 18, 2017 (Investorideas.com Newswire) Viridian Capital Advisors, LLC reports on its weekly Viridian Activity in the Cannabis Industry for the week ending October 13, 2017.

Tuesday 17th October 2017

TEVA Pharmaceuticals-Aktie: Absenkung der Bonitätsnote? - Aktienanalyse

San Francisco - TEVA Pharmaceuticals-Aktienanalyse von Analyst David Maris von Wells Fargo Advisors: Laut einer Aktienanalyse bestätigt Analyst David Maris von Wells Fargo Advisors seine Erwartung ...

Will Semaglutide Fly with FDA Advisors?

(MedPage Today) -- Increased retinopathy risk in one trial could stymie approval

Allurion Technologies Appoints Four Distinguished Board Members; Secures Term Loan from Silicon Valley Bank

Michael Davin, Gail Zauder, Todd Zavodnick and Krishna Gupta bring a wealth of experience to the growing Allurion Technologies team Silicon Valley Bank term loan further strengthens Allurion’s balance sheet following Series C financing Allurion Technologies, maker of the Elipse® Balloon – the world’s first and only procedureless...

Proscia Announces Newly Formed Board of Advisors

Distinguished scientists to help shape both company and future of digital pathology BALTIMORE (PRWEB) October 17, 2017 Proscia Inc., a data solutions provider for digital pathology, announces today the formation of its Board of Advisors (BOA), further strengthening the company and solidifying its mission to drive the adoption of computational pathology. Proscia’s newly formed BOA includes scien...

New report sheds light on mid-market M&A fees on a global basis

Survey of over 470 investment bankers and M&A advisors aims to provide greater transparency into M&A advisory fees TORONTO (PRWEB) October 17, 2017 Firmex today released new research on M&A advisory fees prepared in conjunction with Divestopedia. Firmex and Divestopedia surveyed 471 investment bankers and M&A advisors globally to compile The M&A Fee Guide 2017 report. To help ...

Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases

Founded to translate discoveries in age-related macular degeneration (AMD) genetics into precision therapeutics for patients Broad pipeline of first-in-class therapeutic candidates with potential in ophthalmology and rare complement-mediated genetic diseases Founders and advisors include leading experts in retin...

Monday 16th October 2017

FDA advisors back gene therapy for rare inherited blindness

The US Food Drug and Administration advisory committee has backed the use of gene therapy to treat a hereditary disease for the first time...

McKesson RxOwnership Expands Support of Independent Pharmacy Ownership

Adds Student Ownership Boot Camp to Ongoing NCPA Pharmacy Ownership Workshop at Annual Convention Expanding its support of independent pharmacy ownership, McKesson’s RxOwnership® team has partnered with the National Community Pharmacists Association (NCPA) to sponsor a series of educational programs aimed at current and future pharmacists considerin...

Sunday 15th October 2017

$16 million funding for Israeli-Australian biotech company

Azura Ophthalmics has received US$16 million in Series B funding to develop treatments for meibomian gland dysfunction (MGD). The funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF), TPG Biotech, OrbiMed and Ganot Capital, will allow the Israeli-Australian company to move into its next clinical stage in the development of novel treatments for MGD — an eye condition w...

Friday 13th October 2017

McKesson Corporation (MCK) Shares Bought by Piedmont Investment Advisors LLC

Piedmont Investment Advisors LLC raised its position in shares of McKesson Corporation by 25.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,523 shares of the company's stock after buying an additional 11,568 shares during the period.

Thursday 12th October 2017

Advisors to FDA Recommend Approval of Gene Therapy for Blindness

Spark Therapeutics's Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one's parents.

Evolva Holding SA: Evolva kündigt den Preis für die Privatplatzierung an Pictet Asset Management und Cologny Advisors LLP an

MEDIENMITTEILUNG Evolva kündigt den Preis für die Privatplatzierung an Pictet Asset Management und Cologny Advisors LLP an DIESE UNTERLAGEN SIND NICHT ZUR (DIREKTEN ODER INDIREKTEN) VERÖFFENTLICHU...

Wednesday 11th October 2017

Q Biomed Announces Favorable Amendment To Debenture Financing

Company and Yorkville Advisors have agreed to extend the maturity of the remaining debt balance for 12 months

Realm Therapeutics Announces Completion of $26 million Private Placement

MALVERN, PA -- (Marketwired) -- 10/12/17 -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces that the private placement of $26 million (the "PIPE") that it previously disclosed on September 21, 2017, was approved by its shareholders at a general meeting held in London on October 9, 2017 and h...


Quick Search
Advertisement
 

News Quicklinks